DoD Duchenne Muscular Dystrophy Idea Development Award | HT9425 23 DMDRP IDA

Opportunity Information: Apply for HT9425 23 DMDRP IDA

The DoD Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) is designed to push forward fresh, early-stage research ideas in Duchenne muscular dystrophy (DMD) that could open up new directions for the field. The program is explicitly aimed at conceptually innovative projects that are still developing but are grounded in a solid scientific rationale and a clear, testable hypothesis. In practice, this means the award is looking for high-risk, high-reward studies that may be exploratory in nature but are structured enough to generate meaningful, decision-driving data. The intent is to help investigators produce results that could reshape understanding of DMD or unlock new approaches that ultimately speed progress toward better outcomes for individuals living with DMD.

A central theme of the award is that innovation and impact are not optional. Competitive applications are expected to do more than propose strong science; they must clearly explain what makes the idea genuinely new (for example, introducing a new paradigm, challenging current assumptions, or approaching a persistent problem from an unconventional angle). At the same time, applicants must make a convincing case that, if successful, the work could have a major effect on the direction or pace of DMD research. The opportunity emphasizes that a project can still be considered impactful even if it does not produce immediate clinical changes, as long as it meaningfully advances the research landscape or creates credible pathways toward improved patient outcomes. Proposals that are methodologically excellent but not innovative or not positioned for high potential impact are described as not fitting the purpose of the IDA.

The FY23 IDA also places a strong spotlight on New Investigators, both to support early-career researchers and to bring new expertise into DMD. Two New Investigator tracks are highlighted. The New Investigator - Early Stage category is intended for independent investigators who are early in their first faculty appointment (or equivalent), enabling them to compete in a pool separate from more established researchers. The New Investigator - Transitioning category is tailored to established investigators (at or above Assistant Professor) who have built careers in fields outside muscular dystrophy and now want to pivot into DMD research, bringing tools, methods, or perspectives that are new to the DMD space. Importantly, applications from New Investigators and Established Investigators are reviewed in separate tracks at both the peer review and programmatic review stages, which is meant to make the competition fairer for applicants at different career points.

Although the award encourages bold ideas, it is not meant to fund pure speculation. Applicants must include preliminary data relevant to DMD to support feasibility of the hypothesis and the proposed approach. That requirement signals that reviewers will be looking for evidence that the concept can be tested and that the team can execute the work, even if the overall direction is higher risk than a typical incremental proposal. For New Investigators in particular, the opportunity strongly encourages collaboration with researchers who have DMD experience and/or other key expertise needed for the project. The burden is on the applicant to explain how each collaboration fills gaps, strengthens the plan, and increases the likelihood that the research question can be answered effectively.

From an administrative and funding standpoint, this is a Department of Defense opportunity managed through the U.S. Army Medical Research Acquisition Activity (USAMRAA). The funding opportunity number is HT9425 23 DMDRP IDA, listed under CFDA 12.420, and it supports science and technology research and development projects through either grants or cooperative agreements. Eligibility is described as unrestricted in the notice (open to any entity type), subject to any additional eligibility clarifications in the full announcement. The posting indicates an expected eight awards. The original timeline for the FY23 posting shows a creation date of June 6, 2023, with an original closing date of August 23, 2023.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Duchenne Muscular Dystrophy Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 06, 2023.
• Applicants must submit their applications by Aug 23, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 8 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 DMDRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: